Korean Biopharma Legal

  An article written by Editage insights, on "Careers outside academia: How her PhD helps Woojin Lee give legal advice to bioscience companies".  Link shared below: Link  

 Introducing my latest video partnering with the ‘Korean Pharmaceutical and Bio-pharma Manufacturers Association’ on the topic of  'Korean Mergers & Acquitisions of pharmaceutical and life science companies'. Youtube video link:  https://www.youtube.com/watch?v=Pwdpyq71ngY&t=26s

Earlier this year, The 'Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA)' officially launched the 'Convergence AI Institute for Drug Discovery(CAIID)' and held the grand opening ceremony on January 31st. The South Korean CAIID aims to serve as a hub for jointly planning and executing digital convergence research and aims to establish safe utilization platform for diverse data, which may enhance the performance of AI.  The CAIID's head Hwajong Kim stated, "Currently, pharmaceutical companies are collaborating individually with AI companies. However, there is no perfect match between the data held by pharmaceutical companies and the advantages of each solution provider." He continued, "Since each pharmaceutical company possesses different data, the approach to AI should also vary. However, at this point, we cannot predict this in advance, which limits us." He emphasized, "It is not a stage to debate whether this business wi

South Korean  GNT Pharma Co. Ltd announced on the 13th of this month, that administering their stroke treatment drug 'Nelonemdaz' to patients within one hour of arrival at the emergency room showed nearly a five-fold improvement in disability compared to a placebo treatment. T he chief investigator of the Phase 3 trial at Seoul Asan Hospital's Neurology Department, presented the key findings at ISC 2024 held at the Phoenix Convention Center in Arizona, USA. It has been reported that  the Phase 3 trial of Nelonemdaz targeted severe stroke patients receiving intravenous thrombolysis within 12 hours of onset. The 496 patients in this trial received medication within 7 hours of onset upon arrival at the emergency room and underwent thrombolysis simultaneously, analyzing disability improvement and safety 12 weeks later.  The efficacy of Nelonemdaz was found to be related to the time of medication administration and thrombolysis. Particularly, among 47 patients who promptly recei

On the first day of this month, the Ministry of Food and Drug Safety and the biotech industry welcomed the acceptance of the bill adding 'Regenerative Medical Institutions' as human cell management by the National Assembly, amending the 'Act On The Safety Of And Support For Advanced Regenerative Medicine And Advanced Biological Products'.  Human Cell Management businesses are operators who collect, import, inspect, process, and supply human cells, which have been mostly in-house product manufacturers or the blood banks. Now that this amendment has been approved, advanced regenerative medical institutions equipped with facilities, equipment, and personnel similar to the standards for human cell management, shall also be recognized as subjects for permits for the management of human cells. This means that advanced regenerative medical institutions can supply raw materials by performing minimal procedures such as simple isolation, washing, freezing, and thawing of cells ob

The global competition for Antibody-Drug Conjugate (ADC) technology, a cutting-edge method in anti-cancer drug development, is intensifying. Major global pharmaceutical companies, including Pfizer, AbbVie, and Johnson & Johnson, invested significantly to secure ADC technology. This trend is also evident in South Korea, with companies like Samsung Biologics and Celltrion leading the race to obtain ADC capabilities. ADC involves attaching drugs that can attack cancer cells to antibodies, offering targeted drug delivery for anti-cancer agents. The technology is gaining attention globally, and the ADC market is expected to reach $19.8 billion by 2028. The interest in ADC further increased with the approval of 'Enhertu,' an ADC drug for breast cancer jointly developed by AstraZeneca and   Daiichi Sankyo. Major global pharmaceutical companies are actively involved in ADC technology, with Pfizer's Seagen acquisition being the largest M&A deal in the sector. Korean companie